FDA has approved antipsychotic for the acute treatment of schizoaffective disorder. Invega (paliperidone) extended-release tablets were approved for the acute treatment of schizoaffective disorder, either as monotherapy or
Inspire Pharmaceuticals has posted a net loss of $9.5m or $0.17 per share for the second quarter which ended on June 30, 2009, compared to a net loss
Germany-based Merck has requested re-examination of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP). It is for the use of Erbitux (cetuximab) in
FDA has announced a consent decree of permanent injunction filed, that prohibits Teva Animal Health, from manufacturing and distributing adulterated veterinary drugs. Under the terms of the consent
Advanced Life Sciences (ADLS) has received a complete response letter from FDA, regarding its New Drug Application (NDA) for Restanza (cethromycin) for the outpatient treatment of adults with
Allergan reported $0.58 diluted earnings per share attributable to stockholders compared to $0.47 diluted earnings per share attributable to stockholders reported for the second quarter of 2008. Allergan’s
Law firm, Izard Nobel has filed a lawsuit seeking class action status in the US District Court for the District of Massachusetts. The case has been filed on
Medarex has posted net loss for the quarter ended June 30, 2009 at $29.2 million, or $0.23 per share, as compared to a net loss of $53.1 million,
FDA’s Arthritis Advisory Committee has confirmed that it will review Auxilium’s Xiaflex, during an advisory committee hearing at the Holiday Inn in Gaithersburg, MD on September 16, 2009.
Antigenics has entered into definitive agreements to sell in a private placement of approximately 5 million shares of its common stock at a price of $2.00 per share.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.